Biotricity (BTCY) 10-Q 19 Feb 25 2025 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Dec. 31, 2024	Feb. 18, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--03-31
Entity File Number	001-40761
Entity Registrant Name	BIOTRICITY INC.
Entity Central Index Key	0001630113
Entity Tax Identification Number	30-0983531
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	203 Redwood Shores Parkway
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	(650)
Local Phone Number	832-1626
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,751,756
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Mar. 31, 2024
CURRENT ASSETS
Cash	$ 509,601	$ 786,060
Accounts receivable, net	1,235,867	1,468,655
Inventory [Note 3]	1,570,085	1,879,402
Deposits and other receivables	1,545,790	336,456
Total current assets	4,861,343	4,470,573
Deposits and other receivables [Note 10]	112,972	85,000
Long-term accounts receivable	82,607	149,907
Property and equipment [Note 12]	11,087	15,552
Operating right of use assets [Note 10]	919,394	1,221,593
TOTAL ASSETS	5,987,403	5,942,625
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	8,407,458	9,473,118
Convertible promissory notes and short term loans [Note 5]	9,409,106	9,376,471
Term loan, current	2,400,000	2,400,000
Derivative liabilities [Note 8]	412,941	991,866
Operating lease obligations, current [Note 10]	511,922	457,371
Total current liabilities	21,141,427	22,698,826
Federally guaranteed loans [Note 7]	870,800	870,800
Term loan [Note 6]	11,724,476	9,985,033
Derivative liabilities [Note 8]	1,507,271	1,435,668
Operating lease obligations	539,398	929,115
TOTAL LIABILITIES	35,783,372	35,919,442
MEZZANINE EQUITY
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 shares authorized as of December 31, 2024 and March 31, 2024, respectively, 410 and 265 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively [Note 9]	2,143,197	1,488,920
STOCKHOLDERS’ DEFICIENCY
Common stock $0.001 par value, 125,000,000 shares authorized as at December 31, 2024, and March 31, 2024, respectively. Issued and outstanding common shares: 24,394,442 and 9,353,768 as at December 31, 2024 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at December 31, 2024 and March 31, 2024, respectively [Note 9]	24,556	9,515
Shares to be issued 1,005,939 and 324,276 shares of common stock as at December 31, 2024 and March 31, 2024, respectively) [Note 9]	298,543	269,065
Additional paid-in-capital	105,154,121	95,723,083
Accumulated other comprehensive (loss) / income	3,265	32,378
Accumulated deficit	(137,419,652)	(127,499,785)
Total stockholders’ deficiency	(31,939,166)	(31,465,737)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY	5,987,403	5,942,625
Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value	1	1
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value		$ 6

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Mar. 31, 2024
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	24,394,442	9,353,768
Common stock, shares outstanding	24,394,442	9,353,768
Common stock, other shares outstanding	160,672	160,672
Common stock shares to be issued	1,005,939	324,276
Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	9,979,400	9,979,400
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Series B Convertible Redeemable Preferred Stock [Member]
Series B converible redeemable preferred stock, par value	$ 0.001	$ 0.001
Series B converible redeemable preferred stock, authorized	600	600
Series B converible redeemable preferred stock, shares issued	410	265
Series B converible redeemable preferred stock, shares outstanding	410	265
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	200	6,304
Preferred stock, shares outstanding	200	6,304

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
REVENUE	$ 3,619,108	$ 2,972,972	$ 10,087,697	$ 8,885,034
Cost of Revenue	855,140	804,986	2,501,387	2,801,066
GROSS PROFIT	2,763,968	2,167,986	7,586,310	6,083,968
OPERATING EXPENSES
Selling, general and administrative expenses	2,381,734	2,996,804	7,596,717	10,004,350
Research and development expenses	551,216	452,956	1,583,093	1,863,551
TOTAL OPERATING EXPENSES	2,932,950	3,449,760	9,179,810	11,867,901
LOSS FROM OPERATIONS	(168,982)	(1,281,774)	(1,593,500)	(5,783,933)
Interest expense	(849,538)	(790,080)	(2,370,286)	(2,203,860)
Accretion and amortization expenses [Note 5,6]	(291,128)	(422,706)	(1,775,744)	(1,576,345)
Change in fair value of derivative liabilities [Note 8]	32,339	(326,683)	(468,280)	(244,014)
Gain (loss) upon convertible promissory notes conversion and redemption [Note 9]	(17,357)	2,148	(149,658)	15,280
Other income (expense) [Note 9]	65,512	11,004	(127,974)	(118,941)
NET LOSS BEFORE INCOME TAXES	(1,229,154)	(2,808,091)	(6,485,442)	(9,911,813)
Income taxes [Note 3]
NET LOSS BEFORE DIVIDENDS	(1,229,154)	(2,808,091)	(6,485,442)	(9,911,813)
Preferred Stock Dividends	(89,392)	(237,904)	(379,745)	(617,043)
Deemed Dividends [Note 9]			(3,054,680)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(1,318,546)	(3,045,995)	(9,919,867)	(10,528,856)
Translation adjustment	76,680	(204,501)	(29,113)	(99,091)
COMPREHENSIVE LOSS	$ (1,241,866)	$ (3,250,496)	$ (9,948,980)	$ (10,627,947)
LOSS PER SHARE, BASIC	$ (0.054)	$ (0.339)	$ (0.498)	$ (1.191)
LOSS PER SHARE, DILUTED	$ (0.054)	$ (0.339)	$ (0.498)	$ (1.191)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	24,232,369	8,979,430	19,916,489	8,842,890
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	24,232,369	8,979,430	19,916,489	8,842,890

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficiency (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Shares to be Issued [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total	Series B Convertible Redeemable Preferred Stock [Member]	Mezzanine Equity [Member]
Balance at Mar. 31, 2023	$ 7	$ 8,753	$ 24,999	$ 92,844,478	$ (152,797)	$ (112,570,825)	$ (19,845,385)
Balance, shares at Mar. 31, 2023	6,305	8,752,510	3,955
Issuance of common stock		$ 58		119,227			119,285
Issuance of common stock, shares		57,743
Issuance of shares for services [Note 9]		$ 47		45,900			45,947
Issuance of shares for services [Note 9], shares		47,125
Stock based compensation - ESOP [Note 9]				544,655			544,655
Translation adjustment					(99,091)		(99,091)
Net loss before dividends for the period						(9,911,813)	(9,911,813)
Preferred stock dividends						(617,043)	(617,043)
Conversion of preferred shares into common shares [Note 9]		$ 562		353,957			354,519
Conversion of preferred shares into common shares [Note 9], shares		562,251
Issuance of warrants for private placement holders [Note 9]				1,524,719			1,524,719
Issuance of warrants for brokers [Note 9]				127,853			127,853
Balance at Dec. 31, 2023	$ 7	$ 9,420	$ 24,999	95,560,789	(251,888)	(123,099,681)	(27,756,354)
Balance, shares at Dec. 31, 2023	6,305	9,419,629	3,955
Balance at Sep. 30, 2023	$ 7	$ 8,811	$ 24,999	93,338,220	(47,387)	(120,053,686)	(26,729,036)
Balance, shares at Sep. 30, 2023	6,305	8,810,253	3,955
Conversion of mezzanine equity into common shares [Note 9], shares		612,062
Issuance of shares for services [Note 9]		$ 47		45,900			45,947
Issuance of shares for services [Note 9], shares		47,125
Stock based compensation - ESOP [Note 9]				170,140			170,140
Translation adjustment					(204,501)		(204,501)
Net loss before dividends for the period						(2,808,091)	(2,808,091)
Preferred stock dividends						(237,904)	(237,904)
Conversion of preferred shares into common shares [Note 9]		$ 562		353,957			354,519
Conversion of preferred shares into common shares [Note 9], shares		562,251
Issuance of warrants for private placement holders [Note 9]				1,524,719			1,524,719
Issuance of warrants for brokers [Note 9]				127,853			127,853
Balance at Dec. 31, 2023	$ 7	$ 9,420	$ 24,999	95,560,789	(251,888)	(123,099,681)	(27,756,354)
Balance, shares at Dec. 31, 2023	6,305	9,419,629	3,955
Conversion of mezzanine equity into common shares [Note 9], shares		320,321
Balance at Mar. 31, 2024	$ 7	$ 9,515	$ 269,065	95,723,083	32,378	(127,499,785)	(31,465,737)
Temporary equity, shares at Mar. 31, 2024								265
Temporary equity, value at Mar. 31, 2024							1,488,920	$ 1,488,920	$ 1,488,920
Balance, shares at Mar. 31, 2024	6,305	9,514,440	344,276
Issuance of common stock		$ 678	$ (583,496)	582,818
Issuance of common stock, shares		678,123	(678,123)
Conversion of mezzanine equity into common shares [Note 9], shares		$ 2,867	$ 65,407	671,281			739,554	$ (428,722)	(428,722)
Conversion of mezzanine equity into common shares [Note 9], shares								(75)
Conversion of mezzanine equity into common shares [Note 9], shares		2,867,448	394,340
Conversion of convertible notes into common shares [Note 9]		$ 1,345	$ 504,927	1,895,464			2,401,736
Conversion of convertible notes into common shares [Note 9], shares		1,344,709	865,446
Issuance of shares for services [Note 9]		$ 100	$ 42,640	68,380			111,120
Issuance of shares for services [Note 9], shares		100,000	80,000
Stock based compensation - ESOP [Note 9]				172,802			172,801
Translation adjustment					(29,113)		(29,113)
Net loss before dividends for the period						(6,485,442)	(6,485,442)
Preferred stock dividends						(379,745)	(379,745)
Issuance of mezzanine equity [Note 9]								$ 1,082,999	1,082,999
Issuance of mezzanine equity [Note 9], shares								220
Issuance of common shares from at-the-market transaction [Note 9]		$ 98		125,129			125,227
Issuance of common shares from at-the-market transaction [Note 9], shares		97,811
Conversion of preferred shares into common shares [Note 9]	$ (6)	$ 8,952		4,925,756			4,934,702
Conversion of preferred shares into common shares [Note 9], shares	(6,104)	8,952,170
Issuance of shares for settlement of accounts payable [Note 9]		$ 1,000		989,408			990,408
Issuance of shares for settlement of accounts payable [Note 9], shares		1,000,413
Deemed Dividend						(3,054,680)	(3,054,680)
Balance at Dec. 31, 2024	$ 1	$ 24,555	$ 298,543	105,154,120	3,265	(137,419,652)	(31,939,166)
Temporary equity, shares at Dec. 31, 2024								410
Temporary equity, value at Dec. 31, 2024							2,143,197	$ 2,143,197	2,143,197
Balance, shares at Dec. 31, 2024	201	24,555,114	1,005,939
Balance at Sep. 30, 2024	$ 1	$ 23,024	$ 142,537	104,842,124	(73,415)	(136,101,106)	(31,166,835)
Temporary equity, shares at Sep. 30, 2024								435
Temporary equity, value at Sep. 30, 2024								$ 2,286,105	2,286,105
Balance, shares at Sep. 30, 2024	201	23,023,933	194,998
Issuance of common stock		$ 70	$ (42,920)	42,850
Issuance of common stock, shares		70,000	(70,000)
Conversion of mezzanine equity into common shares [Note 9], shares		$ 1,431	$ 65,407	197,238			264,076	$ (142,908)
Conversion of mezzanine equity into common shares [Note 9], shares								(25)
Conversion of mezzanine equity into common shares [Note 9]									(142,908)
Conversion of mezzanine equity into common shares [Note 9], shares		1,431,181	394,340
Conversion of convertible notes into common shares [Note 9]			$ 118,519				118,519
Conversion of convertible notes into common shares [Note 9], shares			456,601
Issuance of shares for services [Note 9]		$ 30	$ 15,000	14,970			30,000
Issuance of shares for services [Note 9], shares		30,000	30,000
Stock based compensation - ESOP [Note 9]				56,938			56,938
Translation adjustment					76,680		76,680
Net loss before dividends for the period						(1,229,154)	(1,229,154)
Preferred stock dividends						(89,392)	(89,392)
Balance at Dec. 31, 2024	$ 1	$ 24,555	$ 298,543	$ 105,154,120	$ 3,265	$ (137,419,652)	(31,939,166)
Temporary equity, shares at Dec. 31, 2024								410
Temporary equity, value at Dec. 31, 2024							$ 2,143,197	$ 2,143,197	$ 2,143,197
Balance, shares at Dec. 31, 2024	201	24,555,114	1,005,939

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,229,154)	$ (2,808,091)	$ (6,485,442)	$ (9,911,813)
Adjustments to reconcile net loss to net cash used in operations:
Stock based compensation			172,802	544,655
Issuance of shares for services			111,120	45,947
Accretion and amortization expenses	291,128	422,706	1,775,744	1,576,345
Change in fair value of derivative liabilities	(32,339)	326,683	468,280	244,014
(Gain) loss upon convertible promissory notes conversion and redemption			149,658	(15,280)
Other expense regarding loss on debt modification				59,161
Property and equipment depreciation	1,489	1,489	4,465	4,465
Non-cash lease expense			302,199	271,357
Changes in operating assets and liabilities:
Accounts receivable, net			300,088	(377,579)
Inventory			309,317	288,096
Deposits and other receivables			(1,237,306)	363,704
Accounts payable and accrued liabilities			2,149,683	1,378,808
Net cash used in operating activities			(1,979,392)	(5,528,120)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common shares, net			125,220	119,285	$ 119,285
Issuance of preferred shares, net			1,732,532	1,900,000
Proceeds from convertible debentures, net			1,337,898	2,207,579
Proceeds from short term loan and promissory notes, net			(1,407,544)	744,333	853,030
Preferred Stock Dividend			(23,868)	(18,016)
Net cash provided by financing activities			1,764,239	4,953,181
Net decrease in cash during the period			(215,153)	(574,939)
Effect of foreign currency translation			(215,154)	89,573
Cash, beginning of period			786,060	570,460	570,460
Cash, end of period	$ 509,602	$ 85,094	509,602	85,094	$ 786,060
Supplemental disclosure of cash flow information:
Interest paid			2,432,947	1,638,991
Taxes

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,229,154)	$ (2,808,091)	$ (6,485,442)	$ (9,911,813)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016. The Company (directly and through its subsidiary) is operating a business that develops, manufactures and sells device and platform technologies, and related services, within the remote monitoring segment of preventative care. It is focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

BASIS OF PRESENTATION, MEASUREM

BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION	2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2024 and 2023 and their accompanying notes. The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2025. The Company’s fiscal year-end is March 31. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated. Reclassifications Certain amounts presented in the prior year period have been reclassified to conform to current period consolidated financial statement presentation. Reverse Split On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) share consolidation (the “Reverse Split”) 20,846 All issued and outstanding common stock, common stock per share amounts and corresponding balance sheet accounts contained in the Condensed Consolidated Financial Statements have been retroactively adjusted to reflect this Reverse Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise and conversion price and the number of shares issuable upon the exercise or conversion of all outstanding stock options, warrants, convertible debt and equity instruments to purchase shares of common stock. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Going Concern, Liquidity and Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. The Company continues to commercialize its current product ecosystem, while concurrently continuing in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of December 31, 2024, had an accumulated deficit of $ 137,419,652 16,280,084 Management anticipates the Company will continue on its revenue growth and loss reduction trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company. During the fiscal year ended March 31, 2024, the Company raised funds through short-term loans and promissory notes, net of repayments of $ 853,030 2,962,386 36,897 123,347 119,285 3 Additionally, during the three months ended September 30, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 9,091 2,000,000 1,900,000 110 925,000 220 1,732,532 During the nine months ended December 31, 2024, the Company also raised $ 1,519,000 97,811 125,220 In the course of operating its business, the Company has consistently increased revenues, improved margins and reduced net operating margins and improved metrics that indicate progress towards profitability. In addition to increasing revenues from its clinical customer base, the Company has expanded into new areas of business and business partnerships that management anticipates will propel the Company’s progress in this regard. As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. The Company recognized the following forms of revenue for the three and nine months ended December 31, 2024, and 2023: SCHEDULE OF REVENUE RECOGNITION 2024 2023 2024 2023 Three months ended December 31 Nine months ended December 31 2024 2023 2024 2023 $ $ $ $ Technology fees 3,386,584 2,780,094 9,467,648 8,280,473 Device sales 232,524 192,878 620,049 604,561 Total 3,619,108 2,972,972 10,087,697 8,885,034 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Inventories Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES December 31, 2024 March 31, 2024 $ $ Raw material 896,216 1,128,700 Finished goods 673,869 750,702 Inventories 1,570,085 1,879,402 Significant accounting estimates and assumptions The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: ● Fair value of stock options The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. ● Fair value of warrants In determining the fair value of the warrant issued for services pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) ● Fair value of derivative liabilities In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. ● Functional currency Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. ● Useful life of property and equipment The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. ● Provisions Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. ● Contingencies Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. ● Inventory obsolescence Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) ● Income and other taxes The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credit and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. ● Incremental borrowing rate for lease The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s Condensed Consolidated Financial Statements. Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Cash Cash includes cash on hand and balances with banks. Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Accounts Receivable Accounts receivable consist of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of input that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of December 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 509,601 $ 509,601 $ — $ — Total assets at fair value $ 509,601 $ 509,601 $ — $ — Liabilities: Derivative liabilities, short-term $ 412,941 $ — $ — $ 412,941 Derivative liabilities, long-term 1,507,271 — — 1,507,271 Total liabilities at fair value $ 1,920,212 $ — $ — $ 1,920,212 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 786,060 $ 786,060 $ — $ — Total assets at fair value $ 786,060 $ 786,060 $ — $ — Liabilities: Derivative liabilities, short-term $ 991,866 $ — $ — $ 991,866 Derivative liabilities, long-term 1,435,668 — — 1,435,668 Total liabilities at fair value $ 2,427,534 $ — $ — $ 2,427,534 There were no transfers between fair value hierarchy levels during the three and nine months ended December 31, 2024 and 2023. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 Leasehold improvement 5 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved . BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses. Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited, to executives, management, accounting, operations, corporate communication, financial and administrative consulting services. Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. Segment Information Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of December 31, 2024, and 2023. Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Company’s Condensed Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. In April 2021, the FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As at December 31, 2024 As at March 31, 2024 $ $ Trade and other payables 4,633,563 5,081,992 Accrued liabilities 3,749,644 4,369,576 Deferred revenue 24,252 21,550 Total 8,407,458 9,473,118 Trade and other payables and accrued liabilities as at December 31, 2024 and March 31, 2024 included $ 653,623 1,303,424

CONVERTIBLE PROMISSORY NOTES AN

CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS	5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Series A Convertible Promissory Notes : During the year ended March 31, 2021, the Company issued $ 11,275,500 12 (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the common stock for the 5 trading days prior to the Conversion Date (the conversion price). BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $ 24.00 75 For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company was obligated to issue warrants that accompany the Series A Notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time of the final closing. The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share. Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Series A Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features. For the Series A Notes, the Company recognized debt issuance costs in the amount of $ 2,301,854 8,088,003 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) On December 30, 2022, the Company exchanged $ 500,000 121,500 621,500 12 75 On December 31, 2024, all of the Series A notes had been converted into common shares, with the exception of notes held by two investors, with a remaining face value in the amount of $ 700,000 During the three and nine months ended December 31, 2024, the Company recognized discount amortization of $ nil As of December 31, 2024, and March 31, 2024, the Company recorded $ 248,034 173,762 During the three and nine months ended December 31, 2024, the Company recognized interest expense in the amount of $ 24,848 72,300 Series A Notes that remain outstanding as at December 31, 2024 are beyond their contractual maturity date. The notes continue to accrue interest, and no repayment demand notification has been received from noteholders. Series B Convertible Notes During the year ended March 31, 2021, the Company also issued $ 1,312,500 Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the conversion price. Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. 3 6.36 100,000 9.0 35,417 Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $ 1,240,000 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) The Company recognized debt issuance costs in the amount of $ 10,000 1,312,500 During the year ended March 31, 2022, $ 472,500 34,586 840,000 During the year ended March 31, 2023, $ 555,600 126,833 During the year ended March 31, 2023, $ 126,680 145,682 The redemption price was determined in accordance with the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note 24,408 During the year ended March 31, 2024, the Company redeemed $ 135,710 162,851 18,540 45,681 During the three and nine months ended December 31, 2024, the Company redeemed $ nil 22,009 nil 25,342 nil 8,320 nil 8,320 During the three and nine months ended December 31, 2023, the Company redeemed $ 16,667 119,043 20,000 142,851 2,149 15,281 5,482 39,089 As of December 31, 2024, no Series B Notes remain outstanding. As of December 31, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $ 88,881 88,602 During the three and nine months ended December 31, 2024, the Company recognized interest expense on the Series B Notes in the amount of $ nil 279 697 3,401 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Series C Convertible Notes The Company has issued Series C Notes of $ 1,812,700 1,100,430 The Series C Notes were sold under subscription agreements to accredited investors. The Series C Notes mature one year from the final closing date of the offering and accrue interest at 15 For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Conversion Amount”) could be converted into that number of shares of common stock equal to: the Conversion Amount divided by the “Optional Conversion Price”, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of common stock (or conversion or exercise price per share of common stock of any common stock equivalents) sold in a Qualified Financing (as defined in the Series C note agreements) For Series C Notes, “Mandatory Conversion” of the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty consecutive trading days (the “Measurement Period”) (A) the closing price of the common stock on the applicable trading market is at least $18.00 per share and (B) the dollar value of average daily trades of the common stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the common stock on each of the ten (10) consecutive trading days following such closing is at least $400,000 per trading day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of common stock (or conversion or exercise price per share of common stock of any common stock Equivalents) sold in a Qualified Financing The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time of final closing The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing. Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Series C Notes as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $ 4.18 2.09 1,278,786 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) For the Series C Notes, the Company recognized debt issuance costs of $ 207,361 1,005,829 During the three and nine months ended December 31, 2024, the Company recognized discount amortization of $ 215,998 1,267,666 35,392 1,232,274 During the three and nine months ended December 31, 2023, the Company recognized discount amortization of $ 139,568 320,434 1,471,345 During the three and nine months ended December 31, 2024, convertible notes with a face value of $ 80,000 1,512,700 18,150 240,407 456,601 2,210,155 577,644 184,627 2,467,844 124,969 2,270,898 18,150 240,442 26,819 517,791 59,658 196,945 During the three and nine months ended December 31, 2024, convertible notes with a face value of $ 125,000 29,844 154,844 17,357 As of December 31, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $ 45,688 253,643 During the three and nine months ended December 31, 2024, the Company recognized interest expense in the amounts of $ 15,465 65,184 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Convertible Preferred Notes The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (“Preferred Note”) in the principal amount of $ 1,000,000 12 The Company also issued a Preferred Note on October 25, 2023 in the principal amount of $ 250,000 12 The Company issued a further Preferred Note in January 2024 for a principal amount of $ 114,303 8 The Company also issued a Preferred Note on June 17, 2024, for a principal amount of $ 300,000 12 During the three months ended December 31, 2024, the Company issued $ 869,000 100,000 10 319,000 10 450,000 As of December 31, 2024, and March 31, 2024, the Company recorded accrued interest in the amount of $ 41,978 4,103 During the three and nine months ended December 31, 2024, the Company recognized interest expense in the amount of $ 53,369 121,977 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Other Convertible Notes On January 23, 2023, the Company issued $ 2,000,000 10 45,045 221,621 The conversion of the Notes is automatic upon a Qualified Financing (as defined in the Notes) which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes. During the three and nine months ended December 31, 2024, the Company recognized discount amortization of $ nil During the three and nine months ended December 31, 2023, the Company recognized discount amortization of $ 55,861 166,975 19,428 Other Short-term loans and Promissory Notes In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 400,000 9,999 40 13,995 560,000 nil nil 6,142 nil Nil 66,213 In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $ 800,000 32,000 29,556 13,999 1,120,00 nil 800 11,200 nil 481 150,760 In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $ 600,000 25 December 15, 2023 3 600,000 13,236 12,723 37,808 113,014 On December 30, 2022, the Company extinguished 51,101 270,000 December 31, 2023 248,479 21,521 50,000 270,000 Nil nil nil 7,304 50,000 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $ 300,000 12,000 5,250 11,083 420,000 700,000 28,000 24,500 980,000 59,161 nil 2,800 9,100 16,100 nil 4,152 108,245 300,651 20,000 211,500 In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the “Revolving Facility”) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $ 1.2 0.3 1,718,286 1,286,792 198,000 125,000 1,916,286 1,411,792 117,133 324,851 36,575 23,879 On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 400,000 24,000 14 38,705 540,000 No On August 11, 2023, the Company issued two short term promissory notes (“August 2023 Notes”), each for a principal amount of $ 250,000 500,000 75,000 250,000 25,000 250,000 50,000 72,500 427,500 75,000 125,000 500,000 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) On December 8, 2023, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 630,000 15,750 44 19,195 844,200 nil 443,185 nil 10,023 716 10,023 769 93,895 130,000 497,925 During January 2024, the Company entered into a short term loan agreement with an individual lender that resulted in gross proceeds of $ 140,000 12 85,192 140,000 15,645 nil 54,808 9,544 20,774 During February 2024, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $ 660,504 12 660,932 68,899 7,101 14,682 54,446 On February 2, 2024, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $ 700,000 35,000 35 29,235 1,008,000 nil 581,105 nil 26,879 486 26,879 303 193,015 207,250 656,805 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)

TERM LOAN AND CREDIT AGREEMENT

TERM LOAN AND CREDIT AGREEMENT	9 Months Ended
	Dec. 31, 2024
Term Loan And Credit Agreement
TERM LOAN AND CREDIT AGREEMENT	6. TERM LOAN AND CREDIT AGREEMENT Term Loan On December 21, 2021, the Company entered into a Credit Agreement (“Credit Agreement”) with SWK Funding LLC (“Lender’); as part of this, the Company has borrowed $ 12.4 December 21, 2026 10.5 February 15, 2022 Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment 2.4 600,000 2,400,000 120,000 50,000 193,437 48,484 144,953 12,000,000 1,574,068 Total costs directly in connection to the loan and fair value of warrants was in the amount of $ 1,042,149 364,000 57,536 198,713 The Company and Lender also entered into a Guarantee and Collateral Agreement (“Collateral Agreement”) wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the “IP Security Agreement”) wherein the Credit Agreement is also secured by the Company’s right title and interest in the Company’s Intellectual Property. In November 2024, the Company completed an additional transaction with its term lender to receive an additional $ 635 945 600,000 0.50 1.425 5 For the three and nine months ended December 31, 2024, the amortization of debt discount expense was $ 52,857 157,314 51,950 154,616 Total interest expense on the term loan for the three and nine months ended December 31, 2024, amounted to $ 559,460 1,546,595 The Company had accrued interest payable of $ 720,123 795,656 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)

FEDERALLY GUARANTEED LOAN

FEDERALLY GUARANTEED LOAN	9 Months Ended
	Dec. 31, 2024
Federally Guaranteed Loan
FEDERALLY GUARANTEED LOAN	7. FEDERALLY GUARANTEED LOAN Economic Injury Disaster Loan (“EIDL”) In April 2020, the Company received $ 370,900 The loan has a term of 30 3.75 In May 2021, the Company received an additional $ 499,900 As of December 31, 2024, and March 31, 2024, the Company recorded accrued interest of $ 4,460 26,497 Interest expense on the above loan was $ 8,231 24,603 8,231 24,603

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the nine months ended December 31, 2024 and 2023: SCHEDULE OF DERIVATIVE LIABILITIES Fiscal Year 2025 Fiscal Year 2024 $ $ Derivative liabilities, beginning of period - March 31 1,435,668 759,065 New issuance [Note 9] 649,533 642,417 Change in fair value of derivatives during period 487,272 (142,830 ) Reduction due to preferred shares converted [Note 9] (1,065,202 ) (119,359 ) Conversion to common shares End of derivative treatment Convertible note modification Convertible note redemption Derivative liabilities, end of period 1,507,271 1,139,293 The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the nine months ended December 31, 2024, and 2023: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Dividend yield (%) 12 12 Risk-free rate for term (%) 4.1 5.1 4.7 5.2 Volatility (%) 91.2 194.2 71.9 111.4 Remaining terms (Years) 0.41 1.59 0.34 2.01 Stock price ($ per share) 0.24 1.14 1.15 3.82 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the nine months ended December 31, 2024: December 31, 2024 December 31, 2023 Dividend yield (%) 12 12 Risk-free rate for term (%) 3.7 5.1 5.04 13.68 Volatility (%) 126.4 185.8 76.2 119.1 Remaining terms (Years) 0.72 2 0.25 1.97 Stock price ($ per share) 0.24 1.34 0.64 2.14 In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the nine months ended December 31, 2024, and 2023: SCHEDULE OF DERIVATIVE LIABILITIES Fiscal Year 2025 Fiscal Year 2024 $ $ Balance beginning of period – March 31 991,866 1,008,216 New Issuance — 1,224,933 Conversion to common shares (490,972 ) (39,089 ) Change in fair value of derivative liabilities (32,525 ) 386,845 End of derivative treatment — (1,652,572 ) Convertible note redemption (8,320 ) - Balance end of period – December 31 460,059 928,333 The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the nine months ended December 31, 2024, and 2023, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Risk-free rate for term (%) 4.1 5.2 4.2 5.3 Volatility (%) 91.2 352.4 76.2 126.6 Remaining terms (Years) 0.25 0.5 0.25 1.49 Stock price ($ per share) 0.24 1.45 0.46 3.04

STOCKHOLDERS_ DEFICIENCY

STOCKHOLDERS’ DEFICIENCY	9 Months Ended
	Dec. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIENCY	9. STOCKHOLDERS’ DEFICIENCY (a) Authorized and Issued Stock As at December 31, 2024, the Company is authorized to issue 125,000,000 125,000,000 0.001 10,000,000 10,000,000 0.001 20,000 20,000 600 600 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) At December 31, 2024, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding were 24,555,114 9,514,440 24,394,442 9,353,768 160,672 160,672 200 6,304 410 265 (b ) Series (A) Preferred Stock The number of Series A Preferred Stock issued and outstanding as of December 31, 2024, and 2023 was 200 6,304 The Series A Preferred Stock is junior to the Company’s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the “Purchase Price”) for the Series A Preferred Stock to date has been $ 1,000 Preferred Stock Dividends Dividends shall be paid at the rate of 12 Conversion The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock; on a monthly basis, up to 5 0.001 15 15 Other Adjustments and Rights ● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization. ● The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company’s common stock on an as converted basis. Company Redemption The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) During the nine months ended December 31, 2024, $ 6,104,444 1,071,542 8,952,170 ($7,984,463) ($11,039,142) 3,054,679 (c) Series B Preferred Stock and Mezzanine Equity On September 19, 2023, the Company entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale of 220 9,091 1,900,000 During the three months ended March 31, 2024, the Company issued an additional 110 Series B preferred shares were issued for net proceeds of $ 925,000 . During the three and nine months ended December 31, 2024, the Company issued an additional and 220 Series B preferred shares for net proceeds of $ nil and $ 1,732,532 , respectively. Pursuant to the initial Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the “Certificate of Designations”) with the Nevada Secretary of State designating 600 10,000 The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock. Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (“Dividends”), in shares of common stock or cash on the stated value at an annual rate of 8 15 Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $ 3.50 4.99 19.9 Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock. At any time after the earlier of a holder’s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holder’s receipt of a Triggering Event notice, such holder may require the Company to redeem such holder’s shares of Series B Preferred Stock. Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock. The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to 110 Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity During the three months ended December 31, 2023, 40 612,062 228,727 16,789 119,359 During the three months ended March 31, 2024, 25 320,321 142,908 75,523 During the three and nine months ended December 31, 2024, 25 75 1,431,181 2,867,448 142,908 428,722 25,116 53,554 96,053 256,725 A roll-forward of activity is presented below for the nine months ended December 31, 2024: SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY Fiscal Year 2025 Fiscal Year 2024 $ $ Balance beginning of period – March 31 1,488,920 — Net proceeds received pursuant to the issuance of preferred shares 1,732,532 1,900,000 Recognition of derivative liabilities (Note 8) (649,533 ) (642,417 ) Conversion into common shares (428,722 ) (228,727 ) Balance end of period – December 31 2,143,197 1,028,856 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) (d) Share issuances Share issuances during the nine months ended December 31, 2024 During the three and nine months ended December 31, 2024, the Company issued nil 320,321 In October 2024, the Company issued 1,197,770 common shares on partial conversion of 25 shares of Series B Convertible Redeemable Preferred Stock, and a further 233,441 additional common shares required to complete its conversion obligation of a conversion of 25 shares of Series B Convertible Redeemable Preferred Stock that was triggered on July 11, 2024. During the three and nine months ended December 31, 2024, the Company issued another 1,431,181 2,867,448 25 75 100,000 shares of common stock valued at $ 26,000 to a consultant as part of agreed contract remuneration. and 1,751,502 During the three and nine months ended December 31, 2024, convertible notes with a face value of $ 55,000 1,487,700 456,601 2,210,155 577.644 118,519 2,401,736 88,303 2,234,232 14,973 237,230 18,330 509,302 30,216 167504 During the nine months ended December 31, 2024, $ 6,104,444 1,071,542 8,952,170 ($7,984,463) ($11,039,142) 3,054,679 The Company issued 1,000,413 741,316 249,093 The Company issued 97,811 125,227 In addition, during the nine months ended December 31, 2024, the Company issued 170,000 111,400 During that same period, the Company issued 100,000 26,000 Share issuances during the nine months ended December 31, 2023 The Company sold 36,897 123,347 119,285 3 20,846 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) (e) Shares to be issued Activity during the nine months ended December 31, 2024 During the three months ended December 31, 2024, the Company issued nil During the nine months ended December 31, 2024, the Company issued 320,321 During the three and nine months ended December 31, 2024, Series C Notes with a face value of $ 55,000 1,487,700 456,601 and 2,210,155 577,544 During the three and nine months ended December 31, 2024, the Company recorded the obligation for 30,000 80,000 15,000 42,640 Activity during the nine months ended December 31, 2023 None. (f) Warrant issuances, exercises and other activity Warrant exercises and issuances during the nine months ended December 31, 2024 None. Warrant exercises and issuances during the nine months ended December 31, 2023 During the three months ended December 31, 2023, the Company issued 868,098 69,062 4.18 2.09 1,652,572 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) Warrant activity during the nine months ended December 31, 2024, is indicated below: SCHEDULE OF WARRANTS OUTSTANDING Broker Warrants Consultant and Noteholder Warrants Warrants Issued on Convertible Notes Total As at March 31, 2024 208,927 253,994 868,098 1,331,019 Beginning balance 208,927 253,994 868,098 1,331,019 Expired/cancelled — (15,000 ) — (15,000 ) Exercised — — — — Issued — — — — As at December 31, 2024 208,927 238,894 868,098 1,316,019 Ending balance 208,927 238,894 868,098 1,316,019 Exercise Price $ 2.09 22.50 $ 2.69 14.40 $ 4.18 Expiration Date August 2026 to October 2033 March 2029 to Dec 2032 October 2027 (g) Stock-based compensation 2016 Equity Incentive Plan On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan was initially 1,241,422 During the three and nine months ended December 31, 2024, the Company granted 250,000 291,559 no 56,885 115,863 170,140 544,655 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) The following table summarizes the stock option activities during the nine months ended December 31: SCHEDULE OF STOCK OPTION ACTIVITIES 2024 2023 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Outstanding at March 31, 2024 1,239,873 $ 9.39 1,264,890 $ 9.29 Granted 291,559 $ 1.24 3,585 $ 2.79 Exercised — $ — — $ — Expired/ Forfeited (66,719 ) $ 12.57 (28,214 ) $ 7.80 Outstanding at December 31, 2024 1,464,713 $ 7.71 1,240,261 $ 9.32 The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective nine months periods ended December 31: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Exercise price ($) 0.2899 0.8997 2.79 Risk free interest rate (%) 4.13 4.43 3.85 Expected term (Years) 2.00 6.50 10.0 Expected volatility (%) 103.26 128.43 117.1 Expected dividend yield (%) 0.00 0.00 Fair value of option ($) 0.178 0.733 2.30 Expected forfeiture (attrition) rate (%) 0.00 0.00 2023 Equity Incentive Plan and the Employee Stock Purchase Plans On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Plan’s administrator. The 2023 Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). An aggregate of 5,000,000 The Company also adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible employees of the Company and the Company’s designated subsidiaries the ability to purchase shares of the Company’s common stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase common stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator (the “Administrator”). In no event can any single offering period be longer than 27 months. The purchase price (the “Purchase Price”) for each offering will be established by the Administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (“Section 423 Offering”), in no case may such Purchase Price be less than the lesser of (i) an amount equal to 85 percent of the fair market value on the commencement date, or (ii) an amount not less than 85 percent of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 business days before the end of the offering period (the “Offering Period”). Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participant’s accumulated payroll deductions will buy at the Purchase Price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 business days before the end of an Offering Period (or such earlier date as determined by the Administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant’s lifetime, purchase rights under the ESPP shall be exercisable only by the participant. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)

OPERATING LEASE RIGHT-OF-USE AS

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS	9 Months Ended
	Dec. 31, 2024
Operating Lease Right-of-use Assets And Lease Obligations
OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS	10. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS The Company has one operating lease primarily for office and administration. During December 2021, the Company entered into a new lease agreement. The Company paid $ 85,000 When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4 SCHEDULE OF OPERATING LEASES OBLIGATIONS Fiscal Year 2024 Fiscal Year 2023 Right of Use Asset $ $ Beginning balance at March 31 1,221,593 1,587,492 New leases — — Amortization (302,199 ) (271,357 ) Ending balance at December 31 919,394 1,316,135 2024 2023 Lease Liability $ $ Beginning balance at March 31 1,386,486 1,722,095 New leases — — Repayment and interest accretion, net (335,165 ) (261,072 ) Ending balance at December 31 1,051,320 1,461,023 December 31, 2024 March 31, 2024 Lease Liability $ $ Current portion of operating lease liability 511,922 457,371 Noncurrent portion of operating lease liability 539,398 929,115 The operating lease expense was $ 437,466 420,251 437,466 394,214 The following table represents the contractual undiscounted cash flows for lease obligations as at December 31, 2024: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar year $ 2024 552,293 2025 600,288 2026 565,359 Total undiscounted lease liability 1,717,940 Less imputed interest 666,620 Total 1,051,320

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES There are no claims against the Company that were assessed as significant, which were outstanding as at December 31, 2024 or March 31, 2024 and, consequently, no provision for such has been recognized in the Condensed Consolidated Financial Statements. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	12. PROPERTY AND EQUIPMENT During the year-ended March 31, 2022, the Company purchased leasehold improvements of $ 12,928 5 16,839 5 no 1,489 1,489 4,465 4,465 SCHEDULE OF PROPERTY AND EQUIPMENT Cost Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2024 16,839 12,928 29,767 Additions — — — Disposals — — — Balance at December 31, 2024 16,839 12,928 29,767 Accumulated depreciation Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2024 8,042 6,173 14,215 Depreciation for the period 2,528 1,936 4,465 Disposals — — — Balance at December 31, 2024 10,570 8,109 18,680 Net book value Balance at March 31, 2024 8,797 6,755 15,552 Balance at December 31, 2024 6,269 4,819 11,087

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events during the period from January 1 to February 19, 2025, the date the Condensed Consolidated Financial Statements were issued, pursuant to the requirements of ASC 855, and has determined the following material subsequent events: ● During January and February of 2025, the Company issued $ 337 thousand in unsecured convertible promissory notes to private investors. These notes mature eighteen to twenty-four months from their issuance date, bear 10 ● During January 2025, the Company issued 394,340 25 Convertible Redeemable Preferred Stock.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. The Company recognized the following forms of revenue for the three and nine months ended December 31, 2024, and 2023: SCHEDULE OF REVENUE RECOGNITION 2024 2023 2024 2023 Three months ended December 31 Nine months ended December 31 2024 2023 2024 2023 $ $ $ $ Technology fees 3,386,584 2,780,094 9,467,648 8,280,473 Device sales 232,524 192,878 620,049 604,561 Total 3,619,108 2,972,972 10,087,697 8,885,034 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)
Inventories	Inventories Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. SCHEDULE OF INVENTORIES December 31, 2024 March 31, 2024 $ $ Raw material 896,216 1,128,700 Finished goods 673,869 750,702 Inventories 1,570,085 1,879,402
Significant accounting estimates and assumptions	Significant accounting estimates and assumptions The preparation of the Condensed Consolidated Financial Statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities: ● Fair value of stock options The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. ● Fair value of warrants In determining the fair value of the warrant issued for services pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) ● Fair value of derivative liabilities In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. ● Functional currency Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. ● Useful life of property and equipment The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. ● Provisions Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. ● Contingencies Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. ● Inventory obsolescence Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) ● Income and other taxes The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credit and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. ● Incremental borrowing rate for lease The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s Condensed Consolidated Financial Statements.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method were not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)
Cash	Cash Cash includes cash on hand and balances with banks.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these Condensed Consolidated Financial Statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.
Accounts Receivable	Accounts Receivable Accounts receivable consist of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of input that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of December 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 509,601 $ 509,601 $ — $ — Total assets at fair value $ 509,601 $ 509,601 $ — $ — Liabilities: Derivative liabilities, short-term $ 412,941 $ — $ — $ 412,941 Derivative liabilities, long-term 1,507,271 — — 1,507,271 Total liabilities at fair value $ 1,920,212 $ — $ — $ 1,920,212 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 786,060 $ 786,060 $ — $ — Total assets at fair value $ 786,060 $ 786,060 $ — $ — Liabilities: Derivative liabilities, short-term $ 991,866 $ — $ — $ 991,866 Derivative liabilities, long-term 1,435,668 — — 1,435,668 Total liabilities at fair value $ 2,427,534 $ — $ — $ 2,427,534 There were no transfers between fair value hierarchy levels during the three and nine months ended December 31, 2024 and 2023.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 Leasehold improvement 5 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)
Impairment for Long-Lived Assets	Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment
Leases	Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.
Research and Development	Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved . BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.
Stock Based Compensation	Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited, to executives, management, accounting, operations, corporate communication, financial and administrative consulting services.
Convertible Notes Payable and Derivative Instruments	Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.
Series B Convertible Preferred Stock	Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars)
Preferred Shares Extinguishments	Preferred Shares Extinguishments The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For preferred stock redemptions and conversion, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss.
Segment Information	Segment Information Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of December 31, 2024, and 2023.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s Condensed Consolidated Financial Statements according to the effective date and the adoption has no significant impact on the Company’s Condensed Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. In April 2021, the FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows. BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. There is no significant impact from adopting ASU No. 2023-01 on the Company’s financial condition, results of operations, and cash flows. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to improve the disclosures regarding a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. There is no significant impact from adopting ASU 2023-07 on the Company’s financial condition, results of operations, and cash flows. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (“ASU 2023-09”) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its Condensed Consolidated Financial Statements. The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SCHEDULE OF REVENUE RECOGNITION	The Company recognized the following forms of revenue for the three and nine months ended December 31, 2024, and 2023: SCHEDULE OF REVENUE RECOGNITION 2024 2023 2024 2023 Three months ended December 31 Nine months ended December 31 2024 2023 2024 2023 $ $ $ $ Technology fees 3,386,584 2,780,094 9,467,648 8,280,473 Device sales 232,524 192,878 620,049 604,561 Total 3,619,108 2,972,972 10,087,697 8,885,034
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES December 31, 2024 March 31, 2024 $ $ Raw material 896,216 1,128,700 Finished goods 673,869 750,702 Inventories 1,570,085 1,879,402
SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS	The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS As of December 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 509,601 $ 509,601 $ — $ — Total assets at fair value $ 509,601 $ 509,601 $ — $ — Liabilities: Derivative liabilities, short-term $ 412,941 $ — $ — $ 412,941 Derivative liabilities, long-term 1,507,271 — — 1,507,271 Total liabilities at fair value $ 1,920,212 $ — $ — $ 1,920,212 As of March 31, 2024 Description Total Level 1 Level 2 Level 3 Assets: Cash $ 786,060 $ 786,060 $ — $ — Total assets at fair value $ 786,060 $ 786,060 $ — $ — Liabilities: Derivative liabilities, short-term $ 991,866 $ — $ — $ 991,866 Derivative liabilities, long-term 1,435,668 — — 1,435,668 Total liabilities at fair value $ 2,427,534 $ — $ — $ 2,427,534
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES	SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Office equipment 5 Leasehold improvement 5

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As at December 31, 2024 As at March 31, 2024 $ $ Trade and other payables 4,633,563 5,081,992 Accrued liabilities 3,749,644 4,369,576 Deferred revenue 24,252 21,550 Total 8,407,458 9,473,118

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2024
Debt Instrument [Line Items]
SCHEDULE OF DERIVATIVE LIABILITIES	SCHEDULE OF DERIVATIVE LIABILITIES Fiscal Year 2025 Fiscal Year 2024 $ $ Derivative liabilities, beginning of period - March 31 1,435,668 759,065 New issuance [Note 9] 649,533 642,417 Change in fair value of derivatives during period 487,272 (142,830 ) Reduction due to preferred shares converted [Note 9] (1,065,202 ) (119,359 ) Conversion to common shares End of derivative treatment Convertible note modification Convertible note redemption Derivative liabilities, end of period 1,507,271 1,139,293
SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS	The lattice methodology was used to value the derivative components of Series A Preferred Stock, using the following assumptions during the nine months ended December 31, 2024, and 2023: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Dividend yield (%) 12 12 Risk-free rate for term (%) 4.1 5.1 4.7 5.2 Volatility (%) 91.2 194.2 71.9 111.4 Remaining terms (Years) 0.41 1.59 0.34 2.01 Stock price ($ per share) 0.24 1.14 1.15 3.82 BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2024 (Unaudited) (Expressed in US dollars) The Monte Carlo simulation methodology was used to value the derivative components of Series B Preferred Stock, using the following assumptions during the nine months ended December 31, 2024: December 31, 2024 December 31, 2023 Dividend yield (%) 12 12 Risk-free rate for term (%) 3.7 5.1 5.04 13.68 Volatility (%) 126.4 185.8 76.2 119.1 Remaining terms (Years) 0.72 2 0.25 1.97 Stock price ($ per share) 0.24 1.34 0.64 2.14
Convertible Debt [Member]
Debt Instrument [Line Items]
SCHEDULE OF DERIVATIVE LIABILITIES	SCHEDULE OF DERIVATIVE LIABILITIES Fiscal Year 2025 Fiscal Year 2024 $ $ Balance beginning of period – March 31 991,866 1,008,216 New Issuance — 1,224,933 Conversion to common shares (490,972 ) (39,089 ) Change in fair value of derivative liabilities (32,525 ) 386,845 End of derivative treatment — (1,652,572 ) Convertible note redemption (8,320 ) - Balance end of period – December 31 460,059 928,333
SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS	The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the nine months ended December 31, 2024, and 2023, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Risk-free rate for term (%) 4.1 5.2 4.2 5.3 Volatility (%) 91.2 352.4 76.2 126.6 Remaining terms (Years) 0.25 0.5 0.25 1.49 Stock price ($ per share) 0.24 1.45 0.46 3.04

STOCKHOLDERS_ DEFICIENCY (Table

STOCKHOLDERS’ DEFICIENCY (Tables)	9 Months Ended
	Dec. 31, 2024
Equity [Abstract]
SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY	A roll-forward of activity is presented below for the nine months ended December 31, 2024: SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY Fiscal Year 2025 Fiscal Year 2024 $ $ Balance beginning of period – March 31 1,488,920 — Net proceeds received pursuant to the issuance of preferred shares 1,732,532 1,900,000 Recognition of derivative liabilities (Note 8) (649,533 ) (642,417 ) Conversion into common shares (428,722 ) (228,727 ) Balance end of period – December 31 2,143,197 1,028,856
SCHEDULE OF WARRANTS OUTSTANDING	Warrant activity during the nine months ended December 31, 2024, is indicated below: SCHEDULE OF WARRANTS OUTSTANDING Broker Warrants Consultant and Noteholder Warrants Warrants Issued on Convertible Notes Total As at March 31, 2024 208,927 253,994 868,098 1,331,019 Beginning balance 208,927 253,994 868,098 1,331,019 Expired/cancelled — (15,000 ) — (15,000 ) Exercised — — — — Issued — — — — As at December 31, 2024 208,927 238,894 868,098 1,316,019 Ending balance 208,927 238,894 868,098 1,316,019 Exercise Price $ 2.09 22.50 $ 2.69 14.40 $ 4.18 Expiration Date August 2026 to October 2033 March 2029 to Dec 2032 October 2027
SCHEDULE OF STOCK OPTION ACTIVITIES	The following table summarizes the stock option activities during the nine months ended December 31: SCHEDULE OF STOCK OPTION ACTIVITIES 2024 2023 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Outstanding at March 31, 2024 1,239,873 $ 9.39 1,264,890 $ 9.29 Granted 291,559 $ 1.24 3,585 $ 2.79 Exercised — $ — — $ — Expired/ Forfeited (66,719 ) $ 12.57 (28,214 ) $ 7.80 Outstanding at December 31, 2024 1,464,713 $ 7.71 1,240,261 $ 9.32
SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS	The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective nine months periods ended December 31: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS December 31, 2024 December 31, 2023 Exercise price ($) 0.2899 0.8997 2.79 Risk free interest rate (%) 4.13 4.43 3.85 Expected term (Years) 2.00 6.50 10.0 Expected volatility (%) 103.26 128.43 117.1 Expected dividend yield (%) 0.00 0.00 Fair value of option ($) 0.178 0.733 2.30 Expected forfeiture (attrition) rate (%) 0.00 0.00

OPERATING LEASE RIGHT-OF-USE _2

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Tables)	9 Months Ended
	Dec. 31, 2024
Operating Lease Right-of-use Assets And Lease Obligations
SCHEDULE OF OPERATING LEASES OBLIGATIONS	SCHEDULE OF OPERATING LEASES OBLIGATIONS Fiscal Year 2024 Fiscal Year 2023 Right of Use Asset $ $ Beginning balance at March 31 1,221,593 1,587,492 New leases — — Amortization (302,199 ) (271,357 ) Ending balance at December 31 919,394 1,316,135 2024 2023 Lease Liability $ $ Beginning balance at March 31 1,386,486 1,722,095 New leases — — Repayment and interest accretion, net (335,165 ) (261,072 ) Ending balance at December 31 1,051,320 1,461,023 December 31, 2024 March 31, 2024 Lease Liability $ $ Current portion of operating lease liability 511,922 457,371 Noncurrent portion of operating lease liability 539,398 929,115
SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION	The following table represents the contractual undiscounted cash flows for lease obligations as at December 31, 2024: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION Calendar year $ 2024 552,293 2025 600,288 2026 565,359 Total undiscounted lease liability 1,717,940 Less imputed interest 666,620 Total 1,051,320

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT Cost Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2024 16,839 12,928 29,767 Additions — — — Disposals — — — Balance at December 31, 2024 16,839 12,928 29,767 Accumulated depreciation Office equipment Leasehold improvement Total $ $ $ Balance at March 31, 2024 8,042 6,173 14,215 Depreciation for the period 2,528 1,936 4,465 Disposals — — — Balance at December 31, 2024 10,570 8,109 18,680 Net book value Balance at March 31, 2024 8,797 6,755 15,552 Balance at December 31, 2024 6,269 4,819 11,087

SCHEDULE OF REVENUE RECOGNITION

SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Product Information [Line Items]
Total	$ 3,619,108	$ 2,972,972	$ 10,087,697	$ 8,885,034
Technology Fees [Member]
Product Information [Line Items]
Total	3,386,584	2,780,094	9,467,648	8,280,473
Device Sales [Member]
Product Information [Line Items]
Total	$ 232,524	$ 192,878	$ 620,049	$ 604,561

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Accounting Policies [Abstract]
Raw material	$ 896,216	$ 1,128,700
Finished goods	673,869	750,702
Inventories	$ 1,570,085	$ 1,879,402

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Platform Operator, Crypto Asset [Line Items]
Cash	$ 509,601	$ 786,060
Total assets at fair value	509,601	786,060
Derivative liabilities, short-term	412,941	991,866
Derivative liabilities, long-term	1,507,271	1,435,668
Total liabilities at fair value	1,920,212	2,427,534
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash	509,601	786,060
Total assets at fair value	509,601	786,060
Derivative liabilities, short-term
Derivative liabilities, long-term
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash
Total assets at fair value
Derivative liabilities, short-term
Derivative liabilities, long-term
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash
Total assets at fair value
Derivative liabilities, short-term	412,941	991,866
Derivative liabilities, long-term	1,507,271	1,435,668
Total liabilities at fair value	$ 1,920,212	$ 2,427,534

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)	Dec. 31, 2024	Mar. 31, 2022
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years	5 years

BASIS OF PRESENTATION, MEASUR_2

BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 19, 2023	Jul. 19, 2023	Jun. 29, 2023	Nov. 30, 2024	Oct. 31, 2024	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Accumulated deficit						$ 137,419,652	$ 127,499,785			$ 137,419,652		$ 127,499,785
Working capital deficiency						16,280,084				16,280,084
Proceeds from short term debt				$ 635,000						$ (1,407,544)	$ 744,333	853,030
Debt conversion converted instrument amount												$ 2,962,386
Conversion of convertible securities										97,811		36,897
Gross proceeds from issuance of common stock										$ 125,227		$ 123,347
Proceeds from issuance of common stock										125,220	119,285	$ 119,285
Placement fee percentage												3%
Proceeds from Issuance of Preferred Stock and Preference Stock										1,732,532	1,900,000
Issuance of shares					1,751,502
Net proceeds											$ 119,285
Conversion of mezzanine equity into common shares [Note 9]						$ 264,076				739,554
Private Lender [Member]
Proceeds from issuance of common stock										125,220
Conversion of mezzanine equity into common shares [Note 9]										$ 1,519,000
Number of stock issued during the period convertible, shares										97,811
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued	220					410	265		220	410		265
Preferred Stock, Redemption Price Per Share	$ 9,091								$ 9,091
Proceeds from Debt, Net of Issuance Costs									$ 2,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,900,000								$ 1,900,000
Issuance of shares						1,431,181				2,867,448
Number of stock issued during the period convertible, shares						25	25	40		75
Common Stock [Member]
Stockholders equity reverse stock split			one-for-six (1-for-6) share consolidation (the “Reverse Split”)
Issuance of common shares to adjust for rounding effect of reverse split, shares		20,846
Issuance of shares						70,000				678,123	57,743
Net proceeds						$ 70				$ 678	$ 58
Conversion of mezzanine equity into common shares [Note 9]						$ 1,431				$ 2,867
Number of stock issued during the period convertible, shares						1,431,181	320,321	612,062		2,867,448
Preferred Stock [Member]
Preferred Stock, Shares Issued						1	1			1		1
Net proceeds
Conversion of mezzanine equity into common shares [Note 9]
Preferred Stock [Member] | Series B Preferred Stock [Member]
Issuance of shares							110			220
Net proceeds							$ 925,000			$ 1,732,532

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Payables and Accruals [Abstract]
Trade and other payables	$ 4,633,563	$ 5,081,992
Accrued liabilities	3,749,644	4,369,576
Deferred revenue	24,252	21,550
Total	$ 8,407,458	$ 9,473,118

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($)	Dec. 31, 2024	Mar. 31, 2024
Payables and Accruals [Abstract]
Trade and other payables and accrued liabilities	$ 653,623	$ 1,303,424

CONVERTIBLE PROMISSORY NOTES _2

CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS (Details Narrative) - USD ($)													1 Months Ended					3 Months Ended		7 Months Ended	9 Months Ended		12 Months Ended
	Jun. 17, 2024	Feb. 02, 2024	Dec. 08, 2023	Oct. 25, 2023	Oct. 23, 2023	Aug. 11, 2023	Jul. 18, 2023	Jul. 13, 2023	Mar. 29, 2023	Jan. 23, 2023	Dec. 30, 2022	Dec. 21, 2021	Nov. 30, 2024	Feb. 29, 2024	Jan. 31, 2024	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Sep. 25, 2023
Short-Term Debt [Line Items]
Debt conversion description																								The redemption price was determined in accordance with the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note
Deferred finance costs												$ 193,437
Debt face amount												$ 12,400,000
Adjustment for amortization
Exercise Price													$ 0.50
Warrants issued												57,536
Debt converted amount																							$ 2,962,386
Gains losses on extinguishment of debt																		(17,357)	$ 2,148		(149,658)	$ 15,280
Derivative liabilities																		412,941			412,941		991,866
Issuance of common stock																						119,285
Unsecured convertible promissory notes																		869,000
Gross proceeds													$ 635,000								(1,407,544)	744,333	853,030
Debt instrument term													5 years
Maturity date												Dec. 21, 2026
Finance charge																							50,000
Accrued interest																		720,123			720,123		795,656
Line of credit facility, revolving credit conversion to term loan, description																In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities.
Financing receivables																$ 1,200,000
Inventory financing by facility																$ 300,000
Accounts receivable, net																					1,718,286		1,286,792
Inventory																		198,000			198,000		125,000
Principal outstanding																					1,916,286		1,411,792
Interest expense																		117,133			324,851
Short Term Loan Agreement [Member]
Short-Term Debt [Line Items]
Interest rate															12%
Debt instrument carrying amount																		85,192			85,192		140,000
Interest payable																		15,645			15,645
Debt face amount															$ 140,000
Repayments of loan																		54,808			54,808
Interest expense related to short term loan																		9,544			20,774
Promissory Note Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument carrying amount																		660,932			660,932		660,932
Revolving Credit Facility [Member]
Short-Term Debt [Line Items]
Interest payable																		36,575			36,575		23,879
Other Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Interest rate										10%
Convertible notes payable										$ 2,000,000
Convertible notes payable										45,045
Convertible notes payable										$ 221,621
Notes Payable, Other Payables [Member]
Short-Term Debt [Line Items]
Unamortized issuance cost discount																			19,428			19,428
Adjustment for amortization																			55,861			166,975
Eighteen Month Anniversary [Member]
Short-Term Debt [Line Items]
Interest rate	12%			12%																							12%
Debt face amount																											$ 1,000,000
Debt converted amount	$ 300,000			$ 250,000
Unsecured convertible promissory notes																		$ 450,000
Twenty Four Month Anniversary [Member]
Short-Term Debt [Line Items]
Interest rate															8%
Debt converted amount															$ 114,303
Six Month Anniversary [Member]
Short-Term Debt [Line Items]
Interest rate																		10%			10%
Unsecured convertible promissory notes																		$ 100,000
Twelve Month Anniversary [Member]
Short-Term Debt [Line Items]
Interest rate																		10%			10%
Unsecured convertible promissory notes																		$ 319,000
Series A Convertible Note Holders [Member]
Short-Term Debt [Line Items]
Warrants issued											51,101
Warrant [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																										The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share.
Preferred Stock [Member]
Short-Term Debt [Line Items]
Interest payable																		41,978			$ 41,978		4,103
Interest expense																		53,369			121,977
Issuance of common stock
Two Series A Notes [Member]
Short-Term Debt [Line Items]
Issuance of debt																										$ 11,275,500
Interest rate																										12%
Two Series A Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Placement agent fees description																										The Company was obligated to issue warrants that accompany the Series A Notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time of the final closing.
Series A Notes One [Member]
Short-Term Debt [Line Items]
Description of conversion terms for debt instrument																										(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the common stock for the 5 trading days prior to the Conversion Date (the conversion price).
Debt conversion description																										the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.
Series A Notes One [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																										The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.
Series A Notes Two [Member]
Short-Term Debt [Line Items]
Debt conversion description																										the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.
Conversion price																										$ 24
Volume weighted average price of common stock, percent																										75%
Series A Notes [Member]
Short-Term Debt [Line Items]
Deferred finance costs																									$ 2,301,854
Unamortized issuance cost discount																									8,088,003
Debt face amount																		700,000			700,000
Series A Notes [Member] | Additional Collateralized Bridge Loan Agreement [Member]
Short-Term Debt [Line Items]
Deferred finance costs							$ 28,000
Series A Note [Member]
Short-Term Debt [Line Items]
Debt instrument carrying amount											$ 500,000
Interest payable																		248,034			248,034		173,762
Interest expense																		24,848			72,300
New Convertible Note [Member]
Short-Term Debt [Line Items]
Interest rate											12%
Debt instrument carrying amount											$ 621,500
Interest payable											$ 121,500
Debt instrument interest rate during period											75%
Series B Notes [Member]
Short-Term Debt [Line Items]
Debt conversion description																										The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage.
Deferred finance costs																									10,000
Unamortized issuance cost discount																									1,312,500
Interest payable																		45,688			45,688		253,643
Debt face amount																									840,000
Proceeds from convertible debt																										$ 1,240,000
Debt converted amount																		125,000			125,000			$ 555,600	$ 472,500
Converted instrument shares issued																								126,833	34,586
Debt instrument periodic payment																								$ 126,680
Cash payment																		154,844			154,844			145,682
Convertible notes payable																								$ 24,408
Derivative liabilities																							45,681
Derivative liabilities																			5,482		8,320	39,089
Debt instrument accrued interest																		29,844			29,844
Series B Notes [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Debt face amount																										$ 1,312,500
Series B Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants and rights outstanding term																										3 years
Series B Notes [Member] | Warrant One [Member]
Short-Term Debt [Line Items]
Exercise Price																										$ 6.36
Warrants issued																										100,000
Series B Notes [Member] | Warrant Two [Member]
Short-Term Debt [Line Items]
Exercise Price																										$ 9
Warrants issued																										35,417
Series B Note [Member]
Short-Term Debt [Line Items]
Interest payable																		88,881			88,881		88,602
Interest expense																			697		279	3,401
Redemption of convertible notes																			16,667		22,009	119,043	135,710
Payment redeemed cash																			20,000		25,342	142,851	162,851
Gains losses on extinguishment of debt																			2,149	$ 17,357	$ 8,320	15,281	18,540
Series C Notes [Member]
Short-Term Debt [Line Items]
Issuance of debt																							1,812,700
Interest rate																		15%			15%
Description of conversion terms for debt instrument																					(i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of common stock (or conversion or exercise price per share of common stock of any common stock equivalents) sold in a Qualified Financing (as defined in the Series C note agreements)
Debt conversion description																					the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty consecutive trading days (the “Measurement Period”) (A) the closing price of the common stock on the applicable trading market is at least $18.00 per share and (B) the dollar value of average daily trades of the common stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the common stock on each of the ten (10) consecutive trading days following such closing is at least $400,000 per trading day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of common stock (or conversion or exercise price per share of common stock of any common stock Equivalents) sold in a Qualified Financing
Unamortized issuance cost discount																		$ 35,392	1,471,345		$ 35,392	1,471,345	1,232,274
Adjustment for amortization																		215,998	139,568		1,267,666	320,434
Proceeds from convertible debt																							1,100,430
Debt converted amount																		$ 55,000			$ 1,487,700
Converted instrument shares issued																		456,601			2,210,155
Warrants derivative					$ 1,278,786
Debt issuance costs																							207,361
Debt instrument derivative liabilities																							1,005,829
Issuance of common stock																		$ 118,519			$ 2,401,736
Debt instrument accrued interest																		14,973			237,230
Derivative liability																		18,330			509,302
Debt instrument accrued interest																		30,216			$ 167,504
Series C Notes [Member] | Note Holders [Member]
Short-Term Debt [Line Items]
Exercise Price					$ 4.18
Series C Notes [Member] | Placement Agents Warrants [Member]
Short-Term Debt [Line Items]
Exercise Price					$ 2.09
Series C Notes [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																					The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes.
Series C Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Placement agent fees description																					The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time of final closing
Series C Notes [Member] | Warrant [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Placement agent fees description																					The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing.
Series C Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest expense																		18,150			$ 240,407
Debt converted amount																		$ 80,000			$ 1,512,700
Converted instrument shares issued																		456,601			2,210,155
Shares recognised as obligation																		577,644
Issuance of common stock																		$ 184,627			$ 2,467,844
Debt settlement value																		124,969			2,270,898
Debt instrument accrued interest																		18,150			240,442
Derivative liability																		26,819			517,791
Debt instrument accrued interest																		59,658			196,945
Series C Note [Member]
Short-Term Debt [Line Items]
Interest expense																		15,465			65,184
Short-term Bridge Loan Agreement [Member] | Collateralized Merchant Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs								$ 24,000									$ 9,999
Debt instrument carrying amount								540,000									560,000
Adjustment for amortization																						6,142
Debt instrument periodic payment								38,705									13,995				0
Gross proceeds								$ 400,000									$ 400,000
Debt instrument term								98 days									280 days
Accretion expense
Short-term Bridge Loan Agreement [Member] | Additional Collateralized Bridge Loan Agreement [Member]
Short-Term Debt [Line Items]
Gross proceeds							700,000
Short-term Bridge Loan Agreement [Member] | Collateralized Merchant Finance Company One [Member]
Short-Term Debt [Line Items]
Deferred finance costs		$ 35,000
Unamortized issuance cost discount																							26,879
Debt instrument carrying amount		1,008,000
Debt face amount																							581,105
Adjustment for amortization																		486			26,879
Debt instrument periodic payment		29,235
Gross proceeds		$ 700,000
Debt instrument term		245 days
Accretion expense																		303			193,015
Repayments of loan																		207,250			656,805
Short-term Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs																	$ 32,000
Debt instrument carrying amount																	1,120
Adjustment for amortization																			800			11,200
Debt instrument periodic payment																	29,556
Gross proceeds																	800,000
Accretion expense																			481			150,760
Repayments of loan																					66,213
Short-term Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | First Four Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment																	13,999
Promissory Note Agreement [Member] | Individual Investor [Member]
Short-Term Debt [Line Items]
Debt instrument carrying amount																	$ 600,000	600,000			600,000		600,000
Interest payable																		13,236			13,236		12,723
Debt instrument interest rate during period																	25%
Interest expense																		37,808			113,014
Maturity date																	Dec. 15, 2023
Early payment penalty provision percentage																	3%
Promissory Note Agreement [Member] | Individual Investor One [Member]
Short-Term Debt [Line Items]
Interest payable																		68,899			68,899		7,101
Debt instrument interest rate during period														12%
Debt face amount														$ 660,504
Interest expense																		14,682			54,446
New Promissory Note [Member]
Short-Term Debt [Line Items]
Unamortized issuance cost discount
Debt instrument carrying amount																		270,000			270,000		270,000
Debt face amount											$ 270,000
Adjustment for amortization																						7,304
Maturity date											Dec. 31, 2023
Debt face amount											$ 248,479
Adjustment carrying value and principal amount											$ 21,521
Accrued interest																		50,000			50,000		50,000
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs									$ 12,000
Debt instrument carrying amount									420,000
Gross proceeds									300,000
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | First Four Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment									5,250
Collateralized Bridge Loan Agreement [Member] | Finance Company [Member] | Remaining Thirty Six Weeks [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment									$ 11,083
Additional Collateralized Bridge Loan Agreement [Member] | Finance Company [Member]
Short-Term Debt [Line Items]
Debt instrument carrying amount							980,000
Adjustment for amortization																			9,100		2,800	16,100
Debt instrument periodic payment							24,500
Accretion expense																			$ 108,245		4,152	$ 300,651
Repayments of loan																		20,000			211,500
Loss on amendment of debt							$ 59,161
Two Short Term Promissory Notes [Member]
Short-Term Debt [Line Items]
Interest payable																		75,000			75,000		75,000
Debt face amount						$ 250,000												72,500			72,500		427,500
Repayments of loan																		125,000			500,000
Administrative fees						75,000
Two Short Term Promissory Notes [Member] | One Investor [Member]
Short-Term Debt [Line Items]
Gross proceeds						500,000
Short Term Promissory Notes One [Member]
Short-Term Debt [Line Items]
Debt face amount						250,000
Administrative fees						$ 25,000
Short Term Promissory Notes Two [Member]
Short-Term Debt [Line Items]
Debt face amount																							250,000
Administrative fees																							50,000
Short Term Bridge Loan Agreement One [Member] | Collateralized Merchant Finance Company [Member]
Short-Term Debt [Line Items]
Deferred finance costs			$ 15,750
Unamortized issuance cost discount																							10,023
Debt instrument carrying amount			844,200
Debt face amount																							$ 443,185
Adjustment for amortization																		716			10,023
Debt instrument periodic payment			19,195
Gross proceeds			$ 630,000
Debt instrument term			308 days
Accretion expense																		769			93,895
Repayments of loan																		$ 130,000			$ 497,925

TERM LOAN AND CREDIT AGREEMENT

TERM LOAN AND CREDIT AGREEMENT (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 21, 2021	Nov. 30, 2024	Nov. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Cash and Cash Equivalents [Line Items]
Debt instrument, face amount	$ 12,400,000
Maturity date	Dec. 21, 2026
Interest rate	10.50%
Interest payments due date	Feb. 15, 2022
Debt instrument, payment terms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment
Principal repayments						$ 600,000		$ 2,400,000
Loans payable current portion				$ 2,400,000		2,400,000
Origination fee amount	$ 120,000
Debt financing	193,437
Professional fee	48,484
Term loan exit fee	144,953	$ 1,425,000
Gross proceeds	12,000,000
Repayment of short term debt	1,574,068
Fair value of warrants	$ 1,042,149
Unpaid interest			$ 364,000	849,538	$ 790,080	2,370,286	$ 2,203,860
Warrants issued	57,536
Issuance of warrants	$ 198,713
Proceeds from short term debt		635,000				(1,407,544)	744,333	853,030
Debt instrument interest amount		$ 945,000
Warrants shares issues		600,000,000
Warrants price per share		$ 0.50
Debt instrument term		5 years
Amortization of debt discount expense				52,857	$ 51,950	157,314	$ 154,616
Interest payable current				720,123		720,123		$ 795,656
Term Loan [Member]
Cash and Cash Equivalents [Line Items]
Interest expense				$ 559,460		$ 1,546,595
Cash [Member]
Cash and Cash Equivalents [Line Items]
Debt financing	$ 50,000

FEDERALLY GUARANTEED LOAN (Deta

FEDERALLY GUARANTEED LOAN (Details Narrative) - USD ($)		1 Months Ended				3 Months Ended		9 Months Ended
	Dec. 21, 2021	Nov. 30, 2024	Nov. 30, 2022	May 31, 2021	Apr. 30, 2020	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Short-Term Debt [Line Items]
Proceeds from loan	$ 12,000,000
Debt instrument term		5 years
Interest expense			$ 364,000			$ 849,538	$ 790,080	$ 2,370,286	$ 2,203,860
Economic Injury Disaster Loan [Member]
Short-Term Debt [Line Items]
Proceeds from loan				$ 499,900	$ 370,900
Debt instrument description					The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months
Debt instrument term					30 years
Debt interest rate					3.75%
Accrued interest						4,460		4,460		$ 26,497
Interest expense						$ 8,231	$ 8,231	$ 24,603	$ 24,603

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES (Details) - USD ($)	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Balance beginning of period – March 31	$ 1,435,668	$ 759,065
New Issuance	649,533	642,417
Change in fair value of derivative liabilities	487,272	(142,830)
Reduction due to preferred shares converted [Note 9]	(1,065,202)	(119,359)
Balance end of period – December 31	1,507,271	1,139,293
Convertible Debt [Member]
Debt Instrument [Line Items]
Balance beginning of period – March 31	991,866	1,008,216
New Issuance		1,224,933
Change in fair value of derivative liabilities	(32,525)	386,845
Conversion to common shares	(490,972)	(39,089)
End of derivative treatment		(1,652,572)
Convertible note redemption	(8,320)
Balance end of period – December 31	$ 460,059	$ 928,333

SCHEDULE OF DERIVATIVE COMPONEN

SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS (Details)	9 Months Ended
	Dec. 31, 2024 $ / shares	Dec. 31, 2023 $ / shares
Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Stock price	$ 0.24	$ 0.46
Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Stock price	$ 1.45	$ 3.04
Measurement Input, Expected Dividend Rate [Member] | Series A Preferred Stock [Member]
Derivative [Line Items]
Derivative liability, measurement input	12	12
Measurement Input, Expected Dividend Rate [Member] | Series B Preferred Stock [Member]
Derivative [Line Items]
Derivative liability, measurement input	12
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	4.1	4.2
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	5.2	5.3
Measurement Input, Risk Free Interest Rate [Member] | Series A Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	4.1	4.7
Measurement Input, Risk Free Interest Rate [Member] | Series A Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	5.1	5.2
Measurement Input, Risk Free Interest Rate [Member] | Series B Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	3.7	5.04
Measurement Input, Risk Free Interest Rate [Member] | Series B Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	5.1	13.68
Measurement Input, Price Volatility [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	91.2	76.2
Measurement Input, Price Volatility [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Derivative liability, measurement input	352.4	126.6
Measurement Input, Price Volatility [Member] | Series A Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	91.2	71.9
Measurement Input, Price Volatility [Member] | Series A Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	194.2	111.4
Measurement Input, Price Volatility [Member] | Series B Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Derivative liability, measurement input	126.4	76.2
Measurement Input, Price Volatility [Member] | Series B Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Derivative liability, measurement input	185.8	119.1
Measurement Input, Expected Term [Member] | Minimum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Remaining terms	3 months	3 months
Measurement Input, Expected Term [Member] | Maximum [Member] | Convertible Note and Warrant Derivative [Member]
Derivative [Line Items]
Remaining terms	6 months	1 year 5 months 26 days
Measurement Input, Expected Term [Member] | Series A Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Remaining terms	4 months 28 days	4 months 2 days
Measurement Input, Expected Term [Member] | Series A Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Remaining terms	1 year 7 months 2 days	2 years 3 days
Measurement Input, Expected Term [Member] | Series B Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Remaining terms	8 months 19 days	3 months
Measurement Input, Expected Term [Member] | Series B Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Remaining terms	2 years	1 year 11 months 19 days
Measurement Input, Share Price [Member] | Series A Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Stock price	$ 0.24	$ 1.15
Measurement Input, Share Price [Member] | Series A Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Stock price	1.14	3.82
Measurement Input, Share Price [Member] | Series B Preferred Stock [Member] | Minimum [Member]
Derivative [Line Items]
Stock price	0.24	0.64
Measurement Input, Share Price [Member] | Series B Preferred Stock [Member] | Maximum [Member]
Derivative [Line Items]
Stock price	$ 1.34	$ 2.14

SCHEDULE OF SERIES B PREFERRED

SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Balance beginning of period – March 31	$ 1,028,856	$ 1,488,920
Net proceeds received pursuant to the issuance of preferred shares		1,732,532	1,900,000
Recognition of derivative liabilities (Note 8)		(649,533)	(642,417)
Conversion into common shares		(428,722)	(228,727)
Balance end of period – December 31	$ 1,488,920	$ 2,143,197	$ 1,028,856

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares	9 Months Ended
	Dec. 31, 2024	Nov. 30, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	1,331,019
Expired/cancelled	(15,000)
Exercised
Issued
Ending balance	1,316,019
Exercise Price		$ 0.50
Broker Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	208,927
Expired/cancelled
Exercised
Issued
Ending balance	208,927
Expiration Date	August 2026 to October 2033
Broker Warrants [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	$ 2.09
Broker Warrants [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	$ 22.50
Consultant Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	253,994
Expired/cancelled	(15,000)
Exercised
Issued
Ending balance	238,894
Expiration Date	March 2029 to Dec 2032
Consultant Warrants [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	$ 2.69
Consultant Warrants [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price	$ 14.40
Warrants Issued on Conversion of Convertible Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	868,098
Expired/cancelled
Exercised
Issued
Ending balance	868,098
Exercise Price	$ 4.18
Expiration Date	October 2027

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITIES (Details) - $ / shares	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding ending balance		$ 2.30
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding beginning balance	1,239,873	1,264,890
Weighted Average Exercise Price, Outstanding beginning balance	$ 9.39	$ 9.29
Number of Options, Granted	291,559	3,585
Weighted Average Exercise Price, Granted	$ 1.24	$ 2.79
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options, Expired/ Forfeited	(66,719)	(28,214)
Weighted Average Exercise Price, Expired/ Forfeited	$ 12.57	$ 7.80
Number of Options, Outstanding ending balance	1,464,713	1,240,261
Weighted Average Exercise Price, Outstanding ending balance	$ 7.71	$ 9.32

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS (Details) - $ / shares	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Exercise price		$ 2.79
Risk free interest rate		3.85%
Expected term		10 years
Expected volatility		117.10%
Expected dividend yield	0%	0%
Fair value of option		$ 2.30
Expected forfeiture (attrition) rate	0%	0%
Minimum [Member]
Exercise price	$ 0.2899
Risk free interest rate	4.13%
Expected term	2 years
Expected volatility	103.26%
Fair value of option	$ 0.178
Maximum [Member]
Exercise price	$ 0.8997
Risk free interest rate	4.43%
Expected term	6 years 6 months
Expected volatility	128.43%
Fair value of option	$ 0.733

STOCKHOLDERS_ DEFICIENCY (Detai

STOCKHOLDERS’ DEFICIENCY (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Jul. 11, 2024	Sep. 19, 2023	Dec. 21, 2021	Oct. 31, 2024	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Nov. 30, 2024	Sep. 30, 2024	Feb. 02, 2016
Class of Stock [Line Items]
Common stock shares authorized					125,000,000	125,000,000			125,000,000		125,000,000
Common stock, par value					$ 0.001	$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares authorized					10,000,000	10,000,000			10,000,000		10,000,000
Preferred stock convertible conversion price					$ 0.001				$ 0.001
Common stock, shares issued					24,394,442	9,353,768			24,394,442		9,353,768
Common stock, other shares, outstanding					160,672	160,672			160,672		160,672
Debt instrument redemption price percentage									110%
Face value			$ 12,400,000
Issuance of preferred shares, net									$ 1,732,532	$ 1,900,000
Number of issued shares				1,751,502
fair value of common shares										119,285
Debt conversion description												The redemption price was determined in accordance with the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note
Conversion of common shares									(428,722)	$ (228,727)
Temporary equity value reduction					142,908				428,722
Reduced accrued dividends liability					25,116				$ 53,554
Shares issue				100,000					100,000
Consultant contract remuneration				$ 26,000					$ 26,000
Instrument amount											$ 2,962,386
Loss on debt conversion									$ 249,093
Number of stock issued during the period convertible, shares									97,811		36,897
Gross proceeds from issuance of common stock									$ 125,227		$ 123,347
Issuance of warrants			$ 198,713
Number of shares sold										36,897
Gross proceeds										$ 123,347
Net proceeds										$ 119,285
Percentage of placement fee and other issuance expenses										3%
Number of additional shares issued										20,846
Shares to be issued with fair value					30,000		$ 45,947		$ 111,120	$ 45,947
Number of warrants issued
Exercise price													$ 0.50
Derivative liabilities					$ 1,507,271	$ 1,435,668			$ 1,507,271		$ 1,435,668
Stock-based compensation									$ 172,802	$ 544,655
2016 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share based payment award number of shares authorized															1,241,422
Stock options granted					250,000		0		291,559	0
Stock-based compensation					$ 56,885		$ 170,140		$ 115,863	$ 544,655
2023 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share based payment award number of shares available for issuance												5,000,000
General and Administrative Expense [Member]
Class of Stock [Line Items]
Issuance of shares for services									170,000
Issuance of warrants									$ 111,400
Series C Notes [Member]
Class of Stock [Line Items]
Converted instrument shares issued					456,601				2,210,155
fair value of common shares					$ 118,519				$ 2,401,736
Debt conversion description									the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty consecutive trading days (the “Measurement Period”) (A) the closing price of the common stock on the applicable trading market is at least $18.00 per share and (B) the dollar value of average daily trades of the common stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the common stock on each of the ten (10) consecutive trading days following such closing is at least $400,000 per trading day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of common stock (or conversion or exercise price per share of common stock of any common stock Equivalents) sold in a Qualified Financing
Instrument amount					55,000				$ 1,487,700
Debt instrument accrued interest					14,973				237,230
Derivative liability					18,330				509,302
Debt instrument accrued interest					$ 30,216				$ 167,504
Number of obligation shares to be issued related to conversion					577,544				577,544
Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					9,979,400	9,979,400			9,979,400		9,979,400
Preferred stock convertible conversion price					$ 0.001	$ 0.001			$ 0.001		$ 0.001
Shares outstanding					201	6,305	6,305	6,305	201	6,305	6,305	6,305		201
Preferred stock, shares issued					1	1			1		1
Preferred stock, shares outstanding					1	1			1		1
fair value of common shares
Shares to be issued with fair value
Common Stock [Member]
Class of Stock [Line Items]
Shares outstanding					24,555,114	9,514,440	9,419,629	8,810,253	24,555,114	9,419,629	9,514,440	8,752,510		23,023,933
Number of issued shares					70,000				678,123	57,743
fair value of common shares					$ 70				$ 678	$ 58
Number of conversion of shares					1,431,181	320,321	612,062		2,867,448
Conversion of common shares						$ 142,908	$ 228,727
Accrued dividends liability							16,789			$ 16,789
Related to the shares					$ 96,053	$ 75,523	$ 119,359		$ 256,725
Issuance of shares for settlement of accounts payable									1,000,413
Issuance of shares for settlement of accounts payable, value									$ 741,316
Issuance of shares for services					30,000		47,125		100,000	47,125
Shares to be issued with fair value					$ 30		$ 47		$ 100	$ 47
Shares to be Issued [Member]
Class of Stock [Line Items]
Shares outstanding					1,005,939	344,276	3,955	3,955	1,005,939	3,955	344,276	3,955		194,998
Number of issued shares					(70,000)				(678,123)
fair value of common shares					$ (42,920)				$ (583,496)
Number of conversion of shares					394,340				394,340
Issuance of shares for services					30,000				80,000
Shares to be issued with fair value					$ 15,000				$ 42,640
Note Holder Warrant [Member]
Class of Stock [Line Items]
Number of warrants issued							868,098
Placement Agent Warrants [Member]
Class of Stock [Line Items]
Number of warrants issued							69,062
Exercise price							$ 2.09			$ 2.09
Note Holder [Member]
Class of Stock [Line Items]
Exercise price							$ 4.18			$ 4.18
Warrant [Member]
Class of Stock [Line Items]
Derivative liabilities							$ 1,652,572			$ 1,652,572
Purchase Agreement [Member] | Beneficiary [Member]
Class of Stock [Line Items]
Ownership percentage		4.99%
Shareholders [Member]
Class of Stock [Line Items]
Common stock, shares issued					24,394,442	9,353,768			24,394,442		9,353,768
Shareholders [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Shares outstanding					24,555,114	9,514,440			24,555,114		9,514,440
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					20,000	20,000			20,000		20,000
Preferred stock convertible conversion price					$ 0.001	$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares issued					200	6,304	6,304		200	6,304	6,304
Preferred stock, shares outstanding					200	6,304	6,304		200	6,304	6,304
Preferred stock, liquidation preference					$ 1,000				$ 1,000
Preferred stock dividend rate percentage									12%
Debt instrument redemption price percentage									5%
Preferred stock convertible conversion price					$ 0.001				$ 0.001
Volume weighted average price percentage									15%
Face value					$ 6,104,444				$ 6,104,444
Accrued dividends					1,071,542				$ 1,071,542
Converted instrument shares issued									8,952,170
Deposit liabilities, accrued interest					$ (7,984,463)				$ (7,984,463)
Stock redeemed or called during period, value									(11,039,142)
Investment company, dividend distribution									$ 3,054,679
Initial conversion price		$ 3.50
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					600	600			600		600
Preferred stock, shares issued		220			410	265		220	410		265
Preferred stock, shares outstanding					410	265			410		265
Preferred stock redemption price per share		$ 9,091						$ 9,091
Issuance of preferred shares, net		$ 1,900,000						$ 1,900,000
Number of issued shares					1,431,181				2,867,448
Debt conversion description		Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount.
Number of conversion of shares					25	25	40		75
Stock issued during period shares conversion of convertible securities					25				75
Issuance of common shares from shares to be issued									320,321
Series B Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Number of issued shares						110			220
fair value of common shares						$ 925,000			$ 1,732,532
Series B Preferred Stock [Member] | Purchase Agreement [Member]
Class of Stock [Line Items]
Preferred stock convertible conversion price		$ 10,000
Preferred stock, shares issued		600
Debt instrument redemption price percentage		110%
Stated value percentage		8%
Series B Preferred Stock [Member] | Purchase Agreement [Member] | Beneficiary [Member]
Class of Stock [Line Items]
Ownership percentage		19.90%
Series B Preferred Stock [Member] | Purchase Agreement [Member] | Maximum [Member]
Class of Stock [Line Items]
Stated value percentage		15%
Series B Convertible Redeemable Preferred Stock [Member]
Class of Stock [Line Items]
Number of issued shares				1,197,770
Number of conversion of shares	25			25
Dividends				$ 233,441,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Number of conversion of shares									2,210,155
Shares recognised as obligation									577.644
Debt settled					$ 88,303				$ 2,234,232
Series C Convertible Note [Member]
Class of Stock [Line Items]
Issuance of common shares from shares to be issued

SCHEDULE OF OPERATING LEASES OB

SCHEDULE OF OPERATING LEASES OBLIGATIONS (Details) - USD ($)	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Operating Lease Right-of-use Assets And Lease Obligations
Operating lease right-of-use asset, beginning balance	$ 1,221,593	$ 1,587,492
Right of use asset, new leases
Right of use asset, amortization	(302,199)	(271,357)
Operating lease right-of-use asset, ending balance	919,394	1,316,135
Lease liability, beginning balance	1,386,486	1,722,095
Lease liability, new leases
Lease liability, repayment and interest accretion, net	(335,165)	(261,072)
Lease liability, ending balance	1,051,320	$ 1,461,023
Current portion of operating lease liability	511,922		$ 457,371
Noncurrent portion of operating lease liability	$ 539,398		$ 929,115

SCHEDULE OF CONTRACTUAL UNDISCO

SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION (Details) - USD ($)	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Operating Lease Right-of-use Assets And Lease Obligations
2024	$ 552,293
2025	600,288
2026	565,359
Total undiscounted lease liability	1,717,940
Less imputed interest	666,620
Total	$ 1,051,320	$ 1,386,486	$ 1,461,023	$ 1,722,095

OPERATING LEASE RIGHT-OF-USE _3

OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average rate	11.40%
Operating cash flows from operating leases	$ 437,466	$ 394,214
Selling, General and Administrative Expenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease expense	$ 437,466	$ 420,251
New Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease deposit liability			$ 85,000

SCHEDULE OF PROPERTY AND EQUI_2

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Cost, beginning balance			$ 29,767
Additions
Disposals
Cost, ending balance	$ 29,767		29,767
Accumulated depreciation, beginning balance			14,215
Depreciation for the period	1,489	$ 1,489	4,465	$ 4,465
Disposals
Accumulated depreciation, ending balance	18,680		18,680
Net book value, beginning balance			15,552
Net book value, ending balance	11,087		11,087
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost, beginning balance			16,839
Additions
Disposals
Cost, ending balance	16,839		16,839
Accumulated depreciation, beginning balance			8,042
Depreciation for the period			2,528
Disposals
Accumulated depreciation, ending balance	10,570		10,570
Net book value, beginning balance			8,797
Net book value, ending balance	6,269		6,269
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost, beginning balance			12,928
Additions
Disposals
Cost, ending balance	12,928		12,928
Accumulated depreciation, beginning balance			6,173
Depreciation for the period			1,936
Disposals
Accumulated depreciation, ending balance	8,109		8,109
Net book value, beginning balance			6,755
Net book value, ending balance	$ 4,819		$ 4,819

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Leasehold improvements					$ 12,928
Furniture & fixtures					$ 16,839
Purchase of property plant and equipment			$ 0	$ 0
Depreciation expenses	$ 1,489	$ 1,489	$ 4,465	$ 4,465
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Furniture & fixtures useful life	5 years		5 years		5 years
Depreciation expenses			$ 1,936
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Furniture & fixtures useful life					5 years

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended
	Jan. 31, 2025	Feb. 28, 2025	Dec. 31, 2024
Subsequent Event [Line Items]
Proceeds from unsecured convertible promissory notes			$ 869,000
Subsequent Event [Member] | Unsecured Convertible Promissory Notes One [Member]
Subsequent Event [Line Items]
Proceeds from unsecured convertible promissory notes		$ 337,000
Interest rate		10%
Subsequent Event [Member] | Convertible Redeemable Preferred Stock [Member]
Subsequent Event [Line Items]
Number of issued shares of partial settlement of residual shares	394,340
Number of stock issued during the period convertible, shares	25